Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test new drug duo in fight against tough lymphomas

NCT ID NCT03150329

Summary

This early-stage study is testing a combination of two drugs, pembrolizumab and vorinostat, for people with certain types of lymphoma that have come back or not responded to prior treatments. The main goals are to check the safety of the combination and find the best dose of vorinostat to use. Researchers hope the two drugs will work better together to help the immune system fight the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

Conditions

Explore the condition pages connected to this study.